Inmaculada Hernandez, PharmD
Inmaculada Hernandez, PharmD, is involved in doctoral studies in Health Services Research and Policy at the University of Pittsburgh. Her work is focused on the use of claims data to study the effectiveness and safety of new drugs in real-world clinical practice, particularly novel oral anticoagulants. She is also interested in evaluating patterns of diffusion and adoption of new drugs and in value-based insurance design.
September 24, 2017
Outcomes-based pricing arrangements for pharmaceuticals are increasingly popular. In this piece, we discuss the impact of the outcomes-based pricing arrangements proposed by Amgen on the pricing of PCSK9 inhibitor therapy, and we provide recommendations for payers on the design of outcomes-based contracts.
Risk of Cardiovascular Events With Oral Contraceptives, Part 2 - Regulating Off-Guideline Prescription
January 04, 2016
Using the case of oral contraceptives as an example, I explain the differences between off-label and off-guideline prescription, and explain how the inappropriate use of oral contraceptives could be reduced by the regulation of off-guideline prescription.
November 10, 2015
Oral contraception, the most widely used contraceptive method in the US, is associated with an increased risk of cardiovascular side effects. Despite increased awareness of this risk over the years, the use of oral contraceptives among women with conditions that place them at high risk for cardiovascular effects is still common.
August 10, 2015
Despite harsh measures imposed by the Eurogroup, a third bailout is arguably a better scenario from the perspective of access to healthcare in Greece than a potential exit from the Eurozone.
July 01, 2015
The health coverage of millions of Americans in 34 states was pending upon the Supreme Court decision on the King v Burwell case. Luckily, common sense prevailed and the Supreme Court based its ruling on the original motivation behind the creation of the exchanges rather than on the plain language used in the provision.
June 15, 2015
The availability of dabigatran 110 mg in the US may be a favorable therapeutic option for patients at high risk of bleeding, who may be willing to accept a higher probability of stroke for a reduced risk of hemorrhage
April 20, 2015
What can the US learn from the UK National Health System? Probably not acute care management, but definitely, primary care and preventive interventions.
April 01, 2015
Aggressive policies that target the use and promotion of off-label use are needed to prevent the use of drugs for non-approved indications with little benefit or with harmful outcomes.